Amid the flurry of discussion surrounding cannabis and its medicinal properties, the Indiana State Department of Health wants to remind the public that not all weed is created equal.
While certain substances like CBD oil have proven to be helpful for the treatment of some illnesses, synthetic versions of cannabis still pose a serious danger. Per the ISDH, synthetic cannabinoids have been connected to incidents of severe bleeding, despite being billed as “legal” and “safe.”
“Synthetic cannabinoids contain hundreds of chemicals, and it is difficult to know what’s in them or how people will react to the ingredients,” State Health Commissioner Dr. Kris Box said in a press release. “These substances can cause severe, even life-threatening, bleeding. We have seen cases increase dramatically overnight in Illinois and know at least one person in Indiana has reported severe bleeding after using synthetic cannabinoids.”
School officials and health-care providers are encouraged by ISDH to ask about a patient’s use of synthetic cannabinoids when they seek treatment for severe or “unusual” bleeding.
State partners up for increased opioid data
In an announcement from hc1.com, the management company and Appriss Health will start to provide state agencies with more comprehensive data pertaining to substance use in Indiana.
Through the hc1 Opioid Dashboard, analysis and diagnostic test results could help improve understanding about the opioid crisis and what needs to be done to combat it. Apriss Health is expected to offer up insight from its prescription-drug monitoring program that reportedly collects “real-time” information about prescriptions.
“Addressing the growing opioid-use disorder problem is a key focus of government officials today; a challenge, until now, has been access to additional leading indicators that allow officials to try to get ahead of the epidemic,” Brad Bostic, chairman and CEO of hc1.com, said in the announcement. “Our partnership with Appriss Health provides a powerful body of data that enables state governments to easily see emerging and current opioid hotspots so they can take action sooner.”
Zimmer Biomet enjoys shoulder milestone
Zimmer Biomet Holdings, Inc. recently announced the first successful surgery involving the company’s trademarked Comprehensive Augmented Baseplate.
Dr. John Sperling, an orthopedic surgeon for Mayo Clinic, carried out the surgery. Zimmer Biomet stated this new baseplate complements its Comprehensive Reverse Shoulder System and reportedly serves as an alternative to bone grafting or other procedures.
“The new Augmented Baseplate rounds out Zimmer Biomet’s Comprehensive Shoulder portfolio and provides solutions that help surgeons with difficult glenoid deformity cases,” Orsa Britton, vice president and general manager of Zimmer Biomet’s global extremities business, said in the announcement.
IU to host MS info session
The Anna Yoder MS Fund, part of the Indiana University School of Medicine-Fort Wayne, wants to help guide families and individuals impacted by MS through the process of working with health care and insurance providers.
The program will see local attorney Anna Trzynka speaking about how to navigate the process of applying and receiving social security disability pay. Dr. Jimmy Yen, identified as a leader in MS research, will also present on the topics of improving communication between patients and doctors as well as discuss some of the strides IU is making in the research of MS.
The free event will start at 6:15 p.m. on April 18 in the Indiana University-Purdue University-Fort Wayne medical school building.